Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andres Forero

Showing results (81-90 of 179) with videos related to

Pageof 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006Mothaffar F Rimawi, Ingrid A Mayer, Andres Forero, et al.
Journal of Hematology & Oncology|March 20, 2014
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignanciesNancy L Bartlett, Robert Chen, Michelle A Fanale, et al.
Journal of Hematology & Oncology|June 13, 2014
A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factorsSven de Vos, Andres Forero-Torres, Stephen M Ansell, et al.
Cancer Immunology Research|March 17, 2016
Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating LymphocytesAndres Forero, Yufeng Li, Dongquan Chen, et al.
Cancer|November 14, 2018
The antitumor effects of entinostat in ovarian cancer require adaptive immunityHaller J Smith, Tyler R McCaw, Angelina I Londono, et al.
Molecular Cancer Therapeutics|February 21, 2014
Effect of niclosamide on basal-like breast cancersAngelina I Londoño-Joshi, Rebecca C Arend, Laura Aristizabal, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 5, 2020
Use of 18F-FDG PET/CT as an Initial Staging Procedure for Stage II-III Breast Cancer: A Multicenter Value AnalysisColby J Hyland, Flora Varghese, Christina Yau, et al.
Cancer|February 26, 2013
Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017Jennifer F De Los Santos, Alan Cantor, Keith D Amos, et al.
Leukemia & Lymphoma|August 12, 2014
Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignanciesAndres Forero-Torres, Nancy L Bartlett, Robert B Berryman, et al.
The Oncologist|March 16, 2019
What Is Important When Making Treatment Decisions in Metastatic Breast Cancer? A Qualitative Analysis of Decision-Making in Patients and OncologistsGabrielle B Rocque, Aysha Rasool, Beverly R Williams, et al.
Pageof 18

Showing results (81-90 of 179) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006Mothaffar F Rimawi, Ingrid A Mayer, Andres Forero, et al.
Journal of Hematology & Oncology|March 20, 2014
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignanciesNancy L Bartlett, Robert Chen, Michelle A Fanale, et al.
Journal of Hematology & Oncology|June 13, 2014
A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factorsSven de Vos, Andres Forero-Torres, Stephen M Ansell, et al.
Cancer Immunology Research|March 17, 2016
Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating LymphocytesAndres Forero, Yufeng Li, Dongquan Chen, et al.
Cancer|November 14, 2018
The antitumor effects of entinostat in ovarian cancer require adaptive immunityHaller J Smith, Tyler R McCaw, Angelina I Londono, et al.
Molecular Cancer Therapeutics|February 21, 2014
Effect of niclosamide on basal-like breast cancersAngelina I Londoño-Joshi, Rebecca C Arend, Laura Aristizabal, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 5, 2020
Use of 18F-FDG PET/CT as an Initial Staging Procedure for Stage II-III Breast Cancer: A Multicenter Value AnalysisColby J Hyland, Flora Varghese, Christina Yau, et al.
Cancer|February 26, 2013
Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017Jennifer F De Los Santos, Alan Cantor, Keith D Amos, et al.
Leukemia & Lymphoma|August 12, 2014
Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignanciesAndres Forero-Torres, Nancy L Bartlett, Robert B Berryman, et al.
The Oncologist|March 16, 2019
What Is Important When Making Treatment Decisions in Metastatic Breast Cancer? A Qualitative Analysis of Decision-Making in Patients and OncologistsGabrielle B Rocque, Aysha Rasool, Beverly R Williams, et al.
Pageof 18